Drug Type Monoclonal antibody |
Synonyms antibody program(X-BODY / Jiangsu Hengrui), mAb program (age related macular degen), PDGF receptor beta targeted mAb(X-Body) + [3] |
Target |
Action inhibitors |
Mechanism mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dystrophy, Macular | Discovery | United States | - | |
Dystrophy, Macular | Discovery | China | - | |
Dystrophy, Macular | Discovery | Hong Kong | - | |
Dystrophy, Macular | Discovery | Taiwan Province | - | |
Neoplasms | Discovery | United States | - |